Search

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Prescription Digital Therapeutics a New Frontier in Mental Health Care

Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia

BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US

The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment

Flying animals to safety with Greater Good Charities

Watch as Julie Ryan-Johnson volunteers to take care of animals being brought to new homes following the Maui wildfires.

A legacy in the making: Working together to spark meaningful change

Discover Jim’s passion for being an advocate for meaningful causes.

Foot & Mouth Disease US Supply Vaccines | Boehringer Ingelheim US

Click here to find out how Boehringer Ingelheim is fighting against foot-and-mouth disease by continuing to supply the US vaccine bank.

Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

Innovation from within

Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.

Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Prescription Digital Therapeutics a New Frontier in Mental Health Care

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia

BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment

Flying animals to safety with Greater Good Charities

A legacy in the making: Working together to spark meaningful change

Foot & Mouth Disease US Supply Vaccines | Boehringer Ingelheim US

Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

Innovation from within

Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

More Health Overview

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction